# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Full Dataset from Phase 2a trial in Parkinson's Disease suggest patients treated with bezisterim experienced significant im...
"Bezisterim" has been approved as the non-proprietary name for NE3107 Data shows how bezisterim may be restoring homeos...
BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug the...
U.S. stocks traded lower toward the end of trading, with the S&P 500 edging lower on Monday. The Dow traded down 0.20% to ...